Advertisement

What the Intensivist Needs to Know About Hematopoietic Stem Cell Transplantation?

  • Brion V. Randolph
  • Stefan O. Ciurea
Reference work entry

Abstract

Hematopoietic stem cell transplantation (HSCT) is a potential curative therapy for some patients with hematologic conditions. There are two main types of HSCT. This includes autologous HSCT, for which the stem cells are obtained from the patient, and allogeneic HSCT, for which the stem cells are obtained from a related or unrelated donor. The most common indications for autologous stem cell transplant are multiple myeloma and relapsed/refractory lymphoma, whereas leukemia and bone marrow failure syndromes remain the most common indications for allogeneic stem cell transplant. This chapter will review the different types, indications, processes, and main complications of HSCT. This chapter will also discuss end-of-life issues that patients and providers face when transplant patients are admitted for the intensive care unit.

Keywords

Stem cell transplant Bone marrow transplant Transplant Autologous Allogeneic Graft-versus-host disease (GVHD) Veno-occlusive disease (VOD) Sinusoidal obstruction syndrome (SOS) Idiopathic pulmonary syndrome 

References

  1. 1.
    Abudayyeh A, Hamdi A, Abdelrahim M, Lin H, Page VD, Rondon G, Andersson BS, Afrough A, Martinez CS, Tarrand JJ, Kontoyiannis DP, Marin D, Gaber AO, Oran B, Chemaly RF, Ahmed S, Abudayyeh I, Olson A, Jones R, Popat U, Champlin RE, Shpall EJ, Rezvani K. Poor immune reconstitution is associated with symptomatic BK polyomavirus viruria in allogeneic stem cell transplant recipients. Transpl Infect Dis. 2017;19(1):e12632.Google Scholar
  2. 2.
    Afessa B, Azoulay E. Critical care of the hematopoietic stem cell transplant recipient. Crit Care Clin. 2010;26:133–50.CrossRefGoogle Scholar
  3. 3.
    Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, Stoppa AM, Hulin C, Benboubker L, Garderet L, Decaux O, Leyvraz S, Vekemans MC, Voillat L, Michallet M, Pegourie B, Dumontet C, Roussel M, Leleu X, Mathiot C, Payen C, Avet-Loiseau H, Harousseau JL, I. F. M. Investigators. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366:1782–91.CrossRefPubMedGoogle Scholar
  4. 4.
    Bach PB, Schrag D, Nierman DM, Horak D, White P Jr, Young JW, Groeger JS. Identification of poor prognostic features among patients requiring mechanical ventilation after hematopoietic stem cell transplantation. Blood. 2001;98:3234–40.CrossRefPubMedGoogle Scholar
  5. 5.
    Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, Apperley J, Slavin S, Pasquini M, Sandmaier BM, Barrett J, Blaise D, Lowski R, Horowitz M. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15:1628–33.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Baugh KA, Tzannou I, Leen AM. Infusion of cytotoxic T lymphocytes for the treatment of viral infections in hematopoetic stem cell transplant patients. Curr Opin Infect Dis. 2018;31:292–300.CrossRefPubMedGoogle Scholar
  7. 7.
    Bayraktar UD, Nates JL. Intensive care outcomes in adult hematopoietic stem cell transplantation patients. World J Clin Oncol. 2016;7:98–105.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Bayraktar UD, Shpall EJ, Liu P, Ciurea SO, Rondon G, de Lima M, Cardenas-Turanzas M, Price KJ, Champlin RE, Nates JL. Hematopoietic cell transplantation-specific comorbidity index predicts inpatient mortality and survival in patients who received allogeneic transplantation admitted to the intensive care unit. J Clin Oncol. 2013;31:4207–14.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Ben-Abraham R, Paret G, Cohen R, Szold O, Cividalli G, Toren A, Nagler A. Diffuse alveolar hemorrhage following allogeneic bone marrow transplantation in children. Chest. 2003;124:660–4.CrossRefPubMedGoogle Scholar
  10. 10.
    Blatt J, Gold SH, Wiley JM, Monahan PE, Cooper HC, Harvey D. Off-label use of recombinant factor VIIa in patients following bone marrow transplantation. Bone Marrow Transplant. 2001;28:405–7.CrossRefPubMedGoogle Scholar
  11. 11.
    Bulley SR, Strahm B, Doyle J, Dupuis LL. Defibrotide for the treatment of hepatic veno-occlusive disease in children. Pediatr Blood Cancer. 2007;48:700–4.CrossRefPubMedGoogle Scholar
  12. 12.
    Cesaro S, Hirsch HH, Faraci M, Owoc-Lempach J, Beltrame A, Tendas A, Baltadakis I, Dalle JH, Koc Y, Toporski J, Styczynski J, Yesilipek MA, Heinz W, Caniglia M, Rascon J, Fauser AA, Michallet M, Lopez-Corral L, Neuburger S, Tridello G, Einsele H. Cidofovir for BK virus-associated hemorrhagic cystitis: a retrospective study. Clin Infect Dis. 2009;49:233–40.CrossRefPubMedGoogle Scholar
  13. 13.
    Chopra R, Eaton JD, Grassi A, Potter M, Shaw B, Salat C, Neumeister P, Finazzi G, Iacobelli M, Bowyer K, Prentice HG, Barbui T. Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study. Br J Haematol. 2000;111:1122–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Congdon CC. Experimental treatment of total-body irradiation injury: a brief review. Blood. 1957;12:746–54.CrossRefPubMedGoogle Scholar
  15. 15.
    Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354:1813–26.CrossRefPubMedGoogle Scholar
  16. 16.
    Corbacioglu S, Greil J, Peters C, Wulffraat N, Laws HJ, Dilloo D, Straham B, Gross-Wieltsch U, Sykora KW, Ridolfi-Luthy A, Basu O, Gruhn B, Gungor T, Mihatsch W, Schulz AS. Defibrotide in the treatment of children with veno-occlusive disease (VOD): a retrospective multicentre study demonstrates therapeutic efficacy upon early intervention. Bone Marrow Transplant. 2004;33:189–95.CrossRefPubMedGoogle Scholar
  17. 17.
    Corbacioglu S, Carreras E, Mohty M, Pagliuca A, Boelens JJ, Damaj G, Iacobelli M, Niederwieser D, Olavarria E, Suarez F, Ruutu T, Verdonck L, Hume R, Nejadnik B, Lai C, Finetto G, Richardson P. Defibrotide for the treatment of hepatic veno-occlusive disease: final results from the international compassionate-use program. Biol Blood Marrow Transplant. 2016;22:1874–82.CrossRefPubMedGoogle Scholar
  18. 18.
    D’Souza A, Fretham C. Current uses and outcomes of hematopoietic cell transplantation (HCT): CIBMTR summary slides. 2017. [Online]. Available: http://www.cibmtr.org [Accessed].
  19. 19.
    Danylesko I, Shimoni A. Second malignancies after hematopoietic stem cell transplantation. Curr Treat Options Oncol. 2018;19:9.CrossRefPubMedGoogle Scholar
  20. 20.
    de Lassence A, Fleury-Feith J, Escudier E, Beaune J, Bernaudin JF, Cordonnier C. Alveolar hemorrhage. Diagnostic criteria and results in 194 immunocompromised hosts. Am J Respir Crit Care Med. 1995;151:157–63.CrossRefPubMedGoogle Scholar
  21. 21.
    El-Zimaity M, Saliba R, Chan K, Shahjahan M, Carrasco A, Khorshid O, Caldera H, Couriel D, Giralt S, Khouri I, Ippoliti C, Champlin R, de Lima M. Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation: donor type matters. Blood. 2004;103:4674–80.CrossRefPubMedGoogle Scholar
  22. 22.
    Faioni EM, Krachmalnicoff A, Bearman SI, Federici AB, Decarli A, Gianni AM, McDonald GB, Mannucci PM. Naturally occurring anticoagulants and bone marrow transplantation: plasma protein C predicts the development of venocclusive disease of the liver. Blood. 1993;81:3458–62.PubMedGoogle Scholar
  23. 23.
    Ferra C, Marcos P, Morgades M, Misis M, Bordeje ML, Ribera JM. Similar prognosis for transplanted and non-transplanted patients with hematological malignancy admitted to the intensive care unit. Med Clin (Barc). 2008;130:573–5.CrossRefGoogle Scholar
  24. 24.
    Ganti AK, Lee SJ, Vose JM, Devetten MP, Bociek RG, Armitage JO, Bierman PJ, Maness LJ, Reed EC, Loberiza FR Jr. Outcomes after hematopoietic stem-cell transplantation for hematologic malignancies in patients with or without advance care planning. J Clin Oncol. 2007;25:5643–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Gilbert C, Vasu TS, Baram M. Use of mechanical ventilation and renal replacement therapy in critically ill hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant. 2013;19:321–4.CrossRefGoogle Scholar
  26. 26.
    Gilli K, Remberger M, Hjelmqvist H, Ringden O, Mattsson J. Sequential Organ Failure Assessment predicts the outcome of SCT recipients admitted to intensive care unit. Bone Marrow Transplant. 2010;45:682–8.CrossRefPubMedGoogle Scholar
  27. 27.
    Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M, Martin PJ, Sandmaier BM, Marr KA, Appelbaum FR, Storb R, McDonald GB. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010;363:2091–101.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Hahn T, McCarthy PL Jr, Hassebroek A, Bredeson C, Gajewski JL, Hale GA, Isola LM, Lazarus HM, Lee SJ, Lemaistre CF, Loberiza F, Maziarz RT, Rizzo JD, Joffe S, Parsons S, Majhail NS. Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors. J Clin Oncol. 2013;31:2437–49.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Hicks K, Peng D, Gajewski JL. Treatment of diffuse alveolar hemorrhage after allogeneic bone marrow transplant with recombinant factor VIIa. Bone Marrow Transplant. 2002;30:975–8.CrossRefPubMedGoogle Scholar
  30. 30.
    Ho VT, Revta C, Richardson PG. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: update on defibrotide and other current investigational therapies. Bone Marrow Transplant. 2008;41:229–37.CrossRefPubMedGoogle Scholar
  31. 31.
    Holstein SA, Jung SH, Richardson PG, Hofmeister CC, Hurd DD, Hassoun H, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, van Besien K, Gentile TG, Isola L, Maziarz RT, Bashey A, Landau H, Martin T, Qazilbash MH, Rodriguez C, McClune B, Schlossman RL, Smith SE, Hars V, Owzar K, Jiang C, Boyd M, Schultz C, Wilson M, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Linker C, Anderson KC, McCarthy PL. Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol. 2017;4:e431–42.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Horan JT, Logan BR, Agovi-Johnson MA, Lazarus HM, Bacigalupo AA, Ballen KK, Bredeson CN, Carabasi MH, Gupta V, Hale GA, Khoury HJ, Juckett MB, Litzow MR, Martino R, Mccarthy PL, Smith FO, Rizzo JD, Pasquini MC. Reducing the risk for transplantation-related mortality after allogeneic hematopoietic cell transplantation: how much progress has been made? J Clin Oncol. 2011;29:805–13.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Hwang YY, Sim J, Leung AY, Lie AK, Kwong YL. BK virus-associated bilateral ureteric stenosis after haematopoietic SCT: viral kinetics and successful treatment. Bone Marrow Transplant. 2013;48:745–6.CrossRefPubMedGoogle Scholar
  34. 34.
    Iguchi A, Kobayashi R, Kaneda M, Kobayashi K. Plasma protein C is a useful clinical marker for hepatic veno-occlusive disease (VOD) in stem cell transplantation. Pediatr Blood Cancer. 2010;54:437–43.CrossRefPubMedGoogle Scholar
  35. 35.
    Jantunen E, Itala M, Lehtinen T, Kuittinen O, Koivunen E, Leppa S, Juvonen E, Koistinen P, Wiklund T, Nousiainen T, Remes K, Volin L. Early treatment-related mortality in adult autologous stem cell transplant recipients: a nation-wide survey of 1482 transplanted patients. Eur J Haematol. 2006;76:245–50.CrossRefPubMedGoogle Scholar
  36. 36.
    Jones RJ, Lee KS, Beschorner WE, Vogel VG, Grochow LB, Braine HG, Vogelsang GB, Sensenbrenner LL, Santos GW, Saral R. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation. 1987;44:778–83.CrossRefPubMedGoogle Scholar
  37. 37.
    Kantrow SP, Hackman RC, Boeckh M, Myerson D, Crawford SW. Idiopathic pneumonia syndrome: changing spectrum of lung injury after marrow transplantation. Transplantation. 1997;63:1079–86.CrossRefGoogle Scholar
  38. 38.
    Khan H, Oberoi S, Mahvash A, Sharma M, Rondon G, Alousi A, Shpall EJ, Kontoyiannis DP, Champlin RE, Ciurea SO. Reversible ureteral obstruction due to polyomavirus infection after percutaneous nephrostomy catheter placement. Biol Blood Marrow Transplant. 2011;17:1551–5.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Lichtenberger JP 3rd, Digumarthy SR, Abbott GF, Shepard JA, Sharma A. Diffuse pulmonary hemorrhage: clues to the diagnosis. Curr Probl Diagn Radiol. 2014;43:128–39.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Loberiza FR, Ganti AK, Armitage JO, Bierman PJ, Bociek RG, Devetten MP, Maness LJ, Vose JM, Lee S. Advance care planning (ACP) prior to hematopoietic stem cell transplantation (HSCT) in patients with cancer is associated with improved survival. J Clin Oncol. 2007;25:9026.Google Scholar
  41. 41.
    Majhail NS. Long-term complications after hematopoietic cell transplantation. Hematol Oncol Stem Cell Ther. 2017;10:220–7.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Majhail NS, Parks K, Defor TE, Weisdorf DJ. Diffuse alveolar hemorrhage and infection-associated alveolar hemorrhage following hematopoietic stem cell transplantation: related and high-risk clinical syndromes. Biol Blood Marrow Transplant. 2006;12:1038–46.CrossRefPubMedGoogle Scholar
  43. 43.
    Mathe G, Thomas ED, Ferrebee JW. The restoration of marrow function after lethal irradiation in man: a review. Transplant Bull. 1959;6:407–9.CrossRefPubMedGoogle Scholar
  44. 44.
    McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, van Besien K, Gentile T, Isola L, Maziarz RT, Gabriel DA, Bashey A, Landau H, Martin T, Qazilbash MH, Levitan D, McClune B, Schlossman R, Hars V, Postiglione J, Jiang C, Bennett E, Barry S, Bressler L, Kelly M, Seiler M, Rosenbaum C, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Anderson KC, Linker C. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366:1770–81.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED. Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology. 1984;4:116–22.CrossRefPubMedGoogle Scholar
  46. 46.
    Myers RM, Hill BT, Shaw BE, Kim S, Millard HR, Battiwalla M, Majhail NS, Buchbinder D, Lazarus HM, Savani BN, Flowers MED, D’Souza A, Ehrhardt MJ, Langston A, Yared JA, Hayashi RJ, Daly A, Olsson RF, Inamoto Y, Malone AK, Defilipp Z, Margossian SP, Warwick AB, Jaglowski S, Beitinjaneh A, Fung H, Kasow KA, Marks DI, Reynolds J, Stockerl-Goldstein K, Wirk B, Wood WA, Hamadani M, Satwani P. Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b-cell lymphoma. Cancer. 2018;124:816–25.CrossRefPubMedGoogle Scholar
  47. 47.
    Neumann F, Lobitz O, Fenk R, Bruns I, Kostering M, Steiner S, Hennersdorf M, Kelm M, Strauer BE, Germing U, Hinke A, Haas R, Kobbe G. The sepsis-related Organ Failure Assessment (SOFA) score is predictive for survival of patients admitted to the intensive care unit following allogeneic blood stem cell transplantation. Ann Hematol. 2008;87:299–304.CrossRefPubMedGoogle Scholar
  48. 48.
    O’Donnell PH, Swanson K, Josephson MA, Artz AS, Parsad SD, Ramaprasad C, Pursell K, Rich E, Stock W, van Besien K. BK virus infection is associated with hematuria and renal impairment in recipients of allogeneic hematopoetic stem cell transplants. Biol Blood Marrow Transplant. 2009;15:1038–1048 e1.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Park SH, Choi SM, Lee DG, Choi JH, Yoo JH, Kim SH, Kim HJ, Cho SG, Eom KS, Lee JW, Min WS, Shin WS, Kim CC. Infectious complications associated with alemtuzumab use for allogeneic hematopoietic stem cell transplantation: comparison with anti-thymocyte globulin. Transpl Infect Dis. 2009;11:413–23.CrossRefPubMedGoogle Scholar
  50. 50.
    Pastores SM, Papadopoulos E, Voigt L, Halpern NA. Diffuse alveolar hemorrhage after allogeneic hematopoietic stem-cell transplantation: treatment with recombinant factor VIIa. Chest. 2003;124:2400–3.CrossRefPubMedGoogle Scholar
  51. 51.
    Peggs KS, Mackinnon S. Immune reconstitution following haematopoietic stem cell transplantation. Br J Haematol. 2004;124:407–20.CrossRefPubMedGoogle Scholar
  52. 52.
    Pene F, Aubron C, Azoulay E, Blot F, Thiery G, Raynard B, Schlemmer B, Nitenberg G, Buzyn A, Arnaud P, Socie G, Mira JP. Outcome of critically ill allogeneic hematopoietic stem-cell transplantation recipients: a reappraisal of indications for organ failure supports. J Clin Oncol. 2006;24:643–9.CrossRefPubMedGoogle Scholar
  53. 53.
    Pihusch M, Bacigalupo A, Szer J, von Depka Prondzinski M, Gaspar-Blaudschun B, Hyveled L, Brenner B. Recombinant activated factor VII in treatment of bleeding complications following hematopoietic stem cell transplantation. J Thromb Haemost. 2005;3:1935–44.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Ramlal R, Sasaki K, Cerrada SL, Srour SA, Chen J, Rondon RG, Rezvani K, Oran B, Olson A, Shpall EJ, Champlin RE, Ciurea SO. Viral reactivation in haploidentical transplants using post-transplantation cyclophosphamide – a single institution experience. Biol Blood Marrow Transplant. 2016;22:S375–6.CrossRefGoogle Scholar
  55. 55.
    Raptis A, Mavroudis D, Suffredini A, Molldrem J, Rhee FV, Childs R, Phang S, Barrett A. High-dose corticosteroid therapy for diffuse alveolar hemorrhage in allogeneic bone marrow stem cell transplant recipients. Bone Marrow Transplant. 1999;24:879–83.CrossRefGoogle Scholar
  56. 56.
    Richardson PG, Elias AD, Krishnan A, Wheeler C, Nath R, Hoppensteadt D, Kinchla NM, Neuberg D, Waller EK, Antin JH, Soiffer R, Vredenburgh J, Lill M, Woolfrey AE, Bearman SI, Iacobelli M, Fareed J, Guinan EC. Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood. 1998;92:737–44.PubMedGoogle Scholar
  57. 57.
    Richardson PG, Murakami C, Jin Z, Warren D, Momtaz P, Hoppensteadt D, Elias AD, Antin JH, Soiffer R, Spitzer T, Avigan D, Bearman SI, Martin PL, Kurtzberg J, Vredenburgh J, Chen AR, Arai S, Vogelsang G, McDonald GB, Guinan EC. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood. 2002;100:4337–43.CrossRefPubMedGoogle Scholar
  58. 58.
    Richardson PG, Riches ML, Kernan NA, Brochstein JA, Mineishi S, Termuhlen AM, Arai S, Grupp SA, Guinan EC, Martin PL, Steinbach G, Krishnan A, Nemecek ER, Giralt S, Rodriguez T, Duerst R, Doyle J, Antin JH, Smith A, Lehmann L, Champlin R, Gillio A, Bajwa R, D’Agostino RB Sr, Massaro J, Warren D, Miloslavsky M, Hume RL, Iacobelli M, Nejadnik B, Hannah AL, Soiffer RJ. Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood. 2016;127:1656–65.CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Rondon G, Saliba RM, Chen J, Ledesma C, Alousi AM, Oran B, Hosing CM, Kebriaei P, Khouri IF, Shpall EJ, Popat UR, Champlin RE, Ciurea SO. Impact of fluid overload as new toxicity category on hematopoietic stem cell transplantation outcomes. Biol Blood Marrow Transplant. 2017;23:2166–71.CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Rubenfeld GD, Crawford SW. Withdrawing life support from mechanically ventilated recipients of bone marrow transplants: a case for evidence-based guidelines. Ann Intern Med. 1996;125:625–33.CrossRefPubMedGoogle Scholar
  61. 61.
    Salat C, Holler E, Kolb HJ, Reinhardt B, Pihusch R, Wilmanns W, Hiller E. Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation. Blood. 1997a;89:2184–8.CrossRefPubMedGoogle Scholar
  62. 62.
    Salat C, Holler E, Wolf C, Kolb HJ, Reinhardt B, Pihusch R, Kramling HJ, Heinemann V, Haller M, Hiller E. Laboratory markers of veno-occlusive disease in the course of bone marrow and subsequent liver transplantation. Bone Marrow Transplant. 1997b;19:487–90.CrossRefPubMedGoogle Scholar
  63. 63.
    Scrobohaci ML, Drouet L, Monem-Mansi A, Devergie A, Baudin B, D’Agay MF, Gluckman E. Liver veno-occlusive disease after bone marrow transplantation changes in coagulation parameters and endothelial markers. Thromb Res. 1991;63:509–19.CrossRefPubMedGoogle Scholar
  64. 64.
    Shulman HM, Gown AM, Nugent DJ. Hepatic veno-occlusive disease after bone marrow transplantation. Immunohistochemical identification of the material within occluded central venules. Am J Pathol. 1987;127:549–58.PubMedPubMedCentralGoogle Scholar
  65. 65.
    Shulman HM, Fisher LB, Schoch HG, Henne KW, McDonald GB. Veno-occlusive disease of the liver after marrow transplantation: histological correlates of clinical signs and symptoms. Hepatology. 1994;19:1171–81.CrossRefPubMedGoogle Scholar
  66. 66.
    Silva Lde P, Patah PA, Saliba RM, Szewczyk NA, Gilman L, Neumann J, Han XY, Tarrand J, Ribeiro R, Gulbis A, Shpall EJ, Jones R, Popat U, Walker JA, Petropoulos D, Chiattone A, Stewart J, El-Zimaity M, Anderlini P, Giralt S, Champlin RE, de Lima M. Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplants is the complex result of BK virus infection, preparative regimen intensity and donor type. Haematologica. 2010;95:1183–90.CrossRefPubMedGoogle Scholar
  67. 67.
    Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, Storer B. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912–9.CrossRefPubMedPubMedCentralGoogle Scholar
  68. 68.
    Soubani AO, Kseibi E, Bander JJ, Klein JL, Khanchandani G, Ahmed HP, Guzman JA. Outcome and prognostic factors of hematopoietic stem cell transplantation recipients admitted to a medical ICU. Chest. 2004;126:1604–11.CrossRefPubMedGoogle Scholar
  69. 69.
    Stenehjem JS, Smeland KB, Murbraech K, Holte H, Kvaloy SO, Wethal T, Kiserud CE, Samersaw-Lund MB. Obstructive and restrictive pulmonary dysfunction in long-term lymphoma survivors after high-dose therapy with autologous stem cell transplantation. Acta Oncol. 2018;57:773–81.CrossRefPubMedGoogle Scholar
  70. 70.
    Strouse C, Richardson P, Prentice G, Korman S, Hume R, Nejadnik B, Horowitz MM, Saber W. Defibrotide for treatment of severe veno-occlusive disease in pediatrics and adults: an exploratory analysis using data from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2016;22:1306–12.CrossRefPubMedPubMedCentralGoogle Scholar
  71. 71.
    Tabbara IA, Ghazal CD, Ghazal HH. Early drop in protein C and antithrombin III is a predictor for the development of venoocclusive disease in patients undergoing hematopoietic stem cell transplantation. J Hematother. 1996;5:79–84.CrossRefPubMedGoogle Scholar
  72. 72.
    Thomas ED, Lochte HL Jr, Lu WC, Ferrebee JW. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Engl J Med. 1957;257:491–6.CrossRefPubMedGoogle Scholar
  73. 73.
    Thomas ED, Lochte HL Jr, Cannon JH, Sahler OD, Ferrebee JW. Supralethal whole body irradiation and isologous marrow transplantation in man. J Clin Invest. 1959a;38:1709–16.CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    Thomas ED, Lochte HL Jr, Ferrebee JW. Irradiation of the entire body and marrow transplantation: some observations and comments. Blood. 1959b;14:1–23.CrossRefPubMedGoogle Scholar
  75. 75.
    Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, Wingard JR, Young JA, Boeckh MJ, Center for International, B, Marrow, R, National Marrow Donor, P, European, B, Marrowtransplant, G, American Society of, B, Marrow, T, Canadian, B, Marrow Transplant, G, Infectious Diseases Society of, A, Society for Healthcare Epidemiology of, A, Association of Medical, M, Infectious Disease, C, Centers for Disease, C, Prevention. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009;15:1143–238.CrossRefPubMedPubMedCentralGoogle Scholar
  76. 76.
    Townsend WM, Holroyd A, Pearce R, Mackinnon S, Naik P, Goldstone AH, Linch DC, Peggs KS, Thomson KJ, Singer M, Howell DC, Morris EC. Improved intensive care unit survival for critically ill allogeneic haematopoietic stem cell transplant recipients following reduced intensity conditioning. Br J Haematol. 2013;161:578–86.CrossRefPubMedPubMedCentralGoogle Scholar
  77. 77.
    Trinkaus MA, Lapinsky SE, Crump M, Keating A, Reece DE, Chen C, Hallett DC, Franke N, Winter A, Mikhael JR. Predictors of mortality in patients undergoing autologous hematopoietic cell transplantation admitted to the intensive care unit. Bone Marrow Transplant. 2009;43:411–5.CrossRefPubMedGoogle Scholar
  78. 78.
    Tzannou I, Papadopoulou A, Naik S, Leung K, Martinez CA, Ramos CA, Carrum G, Sasa G, Lulla P, Watanabe A, Kuvalekar M, Gee AP, Wu MF, Liu H, Grilley BJ, Krance RA, Gottschalk S, Brenner MK, Rooney CM, Heslop HE, Leen AM, Omer B. Off-the-shelf virus-specific T cells to treat BK virus, human herpesvirus 6, cytomegalovirus, Epstein-Barr virus, and adenovirus infections after allogeneic hematopoietic stem-cell transplantation. J Clin Oncol. 2017;35:3547–57.CrossRefPubMedPubMedCentralGoogle Scholar
  79. 79.
    van Vliet M, van den Boogaard M, Donnelly JP, Evers AW, Blijlevens NM, Pickkers P. Long-term health related quality of life following intensive care during treatment for haematological malignancies. PLoS One. 2014;9:e87779.CrossRefPubMedPubMedCentralGoogle Scholar
  80. 80.
    Weiden, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. NEJM. 1979;300:1068.CrossRefPubMedGoogle Scholar
  81. 81.
    Wingard JR, Gastineau DA, Leather HL, Snyder E, Szczepiorkowski ZM. Hematopoietic stem cell transplantation: a handbook for clinicians. AABB; 2009. Bethesda, MD.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Brion V. Randolph
    • 1
  • Stefan O. Ciurea
    • 2
  1. 1.Hematology/OncologyMedical University of South CarolinaCharlestonUSA
  2. 2.The University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations